Full-Time

Therapeutic Account Manager

Liver

Posted on 9/3/2026

Mirum Pharmaceuticals

Mirum Pharmaceuticals

201-500 employees

ASBT inhibitors for rare liver diseases

No salary listed

Omaha, NE, USA

Remote

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Forecasting
CRM
Marketing
Data Analysis

Get referred to Mirum Pharmaceuticals

See people who can refer or advise you

Requirements
  • A bachelor's degree is required.
  • At least 5 years of progressive sales experience in the pharmaceutical or biotechnology industry is required.
  • A demonstrated track record of consistently delivering business results in a complex specialty, rare disease, orphan drug, or high-science market is required.
  • Strong clinical aptitude and the ability to learn, retain, and communicate complex disease-state, diagnostic, mechanism-of-action, clinical-data, and product information are required.
  • Experience with account-based selling across health systems, centers of excellence, multidisciplinary care teams, referral networks, and influential healthcare professionals is required.
  • The ability to use insight-led or challenger-style selling to constructively challenge the status quo, influence behavior, and advance customer decision-making is required.
  • Working knowledge of access and reimbursement dynamics, patient support pathways, and the role of patient services in rare disease markets is required.
  • Strong business acumen and the ability to interpret performance data, identify insights, develop territory and account strategies, and translate plans into consistent field execution are required.
  • Exceptional interpersonal skills, emotional intelligence, communication, presentation, judgment, and the ability to build trust with diverse and highly sophisticated customers are required.
  • Self-motivation, resourcefulness, resilience, organization, and the ability to prioritize and perform independently in a fast-moving, ambiguous environment are required.
  • Demonstrated success partnering cross-functionally with Medical Affairs, Market Access, Patient Services, Marketing, Commercial Training and Effectiveness, Operations, and Analytics is required.
  • Commitment to ethical conduct, compliance, and approved promotional practices, with sound judgment in complex customer and patient-related situations, is required.
  • A valid driver's license and the ability to travel up to 70%, including frequent overnight travel and occasional weekend commitments, are required.
Responsibilities
  • Develop and execute a focused territory business plan aligned with national, zone, and regional priorities, including objectives, customer priorities, resource allocation, and measures of success.
  • Use performance data, customer insights, market intelligence, access dynamics, and competitive trends to identify opportunities, anticipate barriers, and adjust territory strategy and execution.
  • Deliver territory business objectives through prioritization, customer engagement, resource stewardship, and accountability for behaviors and results.
  • Maintain accurate and timely customer records, forecasts, expense reports, administrative documentation, and business updates.
  • Identify, prioritize, and develop high-opportunity accounts, health systems, centers of excellence, and referral networks across pediatric and adult hepatology and gastroenterology.
  • Create and execute customized account plans reflecting the local patient journey, stakeholders, clinical decision-making, referral patterns, access considerations, customer needs, and competitive realities.
  • Build trusted relationships with physicians, advanced practice providers, nurses, pharmacists, office staff, and other care-team members.
  • Map influence and decision-making within complex accounts, establish engagement objectives, and secure next steps that advance account strategy.
  • Coordinate compliant account actions across field partners, clarify ownership, and maintain momentum against agreed priorities and customer needs.
  • Develop and maintain knowledge of rare cholestatic liver diseases, diagnostic pathways, mechanisms of action, clinical data, product profiles, approved uses, safety information, patient support pathways, access and reimbursement, and the competitive landscape.
  • Communicate complex scientific and clinical information clearly, accurately, and credibly, tailoring discussions to each healthcare professional and account.
  • Engage healthcare professionals as a clinically credible peer by asking insightful questions, listening actively, uncovering unmet needs, and connecting evidence and resources to practice.
  • Execute approved promotional programs, resources, and customer engagements in compliance with company policies and regulatory requirements.
  • Help customers identify gaps in disease awareness, patient identification, referral, treatment consideration, and ongoing support across the patient journey.
  • Influence multiple stakeholders without authority, navigate resistance constructively, and balance persistence with judgment, empathy, and respect for customer boundaries.
  • Keep patients and caregivers at the center of territory and account decisions from disease recognition and diagnosis through treatment initiation and persistence.
  • Collaborate compliantly with Market Access and Patient Services partners to help care teams understand resources and navigate appropriate patient-journey barriers.
  • Identify and elevate recurring customer, access, and patient-support barriers and partner with internal teams to improve execution and support.
  • Build productive partnerships with Medical Affairs, Market Access, Patient Services, Marketing, Commercial Training and Effectiveness, Operations, Analytics, and Advocacy.
  • Coordinate account strategy across field roles, align priorities, clarify responsibilities, and ensure consistent follow-through while respecting functional boundaries.
  • Capture and communicate timely, objective, and actionable field insights to inform strategy, messaging, training, resource development, customer experience, and execution priorities.
  • Contribute to business reviews, training programs, team meetings, launch readiness, and cross-functional initiatives; share best practices and support broader organizational success.
  • Operate with ownership, self-motivation, resourcefulness, and initiative in an unstructured, rapidly evolving rare-disease environment.
  • Create appropriate engagement opportunities in underdeveloped accounts and markets, test new approaches, learn quickly, and translate insights into action.
  • Maintain sustained drive and performance through pressure, uncertainty, obstacles, delays, and discouragement, recovering quickly while remaining focused on long-term goals.
  • Seek feedback and apply coaching to strengthen clinical, strategic, and selling capabilities.
  • Model the company's values and standards of ethical conduct, compliance, transparency, inclusion, and respect in internal and external interactions.
Desired Qualifications
  • An advanced degree is preferred.
  • Rare disease experience is highly preferred.
  • Experience in hepatology, gastroenterology, pediatric specialty care, or another complex specialty market is highly desirable.
Mirum Pharmaceuticals

Mirum Pharmaceuticals

View

Mirum Pharmaceuticals develops and commercializes therapies for rare liver diseases. Its lead drug LIVMARLI (maralixibat) is an oral ASBT inhibitor that lowers bile acid buildup to relieve itching in cholestatic conditions such as Alagille syndrome, and the company is pursuing LIVMARLI for additional rare liver diseases, with volixibat as another ASBT inhibitor in its pipeline. The company differentiates itself by focusing on rare pediatric and adult cholestatic diseases and building dedicated commercialization infrastructure in the U.S. and other major markets, including partnerships with physicians, payers, and patient groups to improve patient access. Mirum’s goal is to bring effective therapies to patients with rare bile-duct and liver disorders, expand LIVMARLI indications, and establish a sustainable market presence in key markets.

Company Size

201-500

Company Stage

IPO

Headquarters

Foster City, California

Founded

2018

Get referred to Mirum Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 net product sales reached $176.2 million, and guidance rose to $700 million.
  • Rob Myers starts September 21, 2026, strengthening hepatology leadership before key readouts.
  • Volixibat, brelovitug, and zilurgisertib create multiple catalysts through first-half 2027.

What critics are saying

  • FDA recommended another volixibat Phase 3 on August 5, 2026, delaying PSC filing.
  • If LIVMARLI growth slows, Mirum loses the cash engine funding its pipeline.
  • Zilurgisertib’s September 26, 2026 PDUFA denial would crush sentiment and financing flexibility.

What makes Mirum Pharmaceuticals unique

  • LIVMARLI dominates rare pediatric cholestatic disease with expanding PFIC and biliary atresia labels.
  • Mirum combines commercialization strength with late-stage hepatology pipeline breadth across PSC, HDV, and FOP.
  • Exclusive zilurgisertib rights from Incyte add a near-term rare-disease launch platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
Yahoo Finance
Sep 8th, 2026
Mirum Pharmaceuticals appoints Dr Rob Myers as chief medical officer

Mirum Pharmaceuticals has appointed Dr Rob Myers as chief medical officer, effective 21 September 2026. Dr Myers will lead the company's global medical and clinical development functions. Dr Myers brings over 20 years of experience in drug development, with particular expertise in hepatology. He joins from OrsoBio, where he served as chief medical officer and head of development. Previously, he held senior leadership positions at Gilead Sciences, overseeing clinical development programmes across liver fibrosis, cholestatic liver diseases, and gastrointestinal inflammation. Dr Myers has published more than 200 peer-reviewed papers and has contributed to advancing understanding of primary sclerosing cholangitis. He holds an MD from Western University and a master's degree in epidemiology from the University of Calgary.

CNBC TV18
Aug 20th, 2026
US FDA approves Regeneron's rare bone disorder drug.

US FDA approves Regeneron's rare bone disorder drug. Regeneron's Pasatru has received US FDA approval for adults with FOP after clinical trials showed a significant reduction in abnormal bone formation. By Reuters August 20, 2026, 8:59:40 AM IST (Published) The US FDA on Wednesday (August 19) approved Regeneron's drug for a rare genetic disorder after it significantly reduced abnormal bone formation in certain soft tissues. New York-based Regeneron's shares rose 4%. The drug, garetosmab, branded as Pasatru, was approved to treat adults with fibrodysplasia ossificans progressiva (FOP) - a condition in which muscle, tendon and ligament tissue gradually turns into bone, leading to a "second skeleton" that causes progressive loss of mobility and reduced life expectancy. In a 56-week trial involving 63 participants, Pasatru reduced the development of new bone abnormalities by 94% in patients treated with a 3 mg per kg dose and by 90% in those given a 10 mg per kg dose, compared with a placebo. The drug works by blocking Activin A, a protein involved in triggering abnormal bone growth in patients with FOP. Susan Rhee, a member of Regeneron's clinical team, told Reuters last week that the company plans to start a trial for children later this year. The drug will compete with French drugmaker Ipsen's oral treatment Sohonos, which in 2023 became the only other treatment approved by the US Food and Drug Administration. Incyte and partner Mirum Pharma, as well as privately held Ashibio, are also developing treatments for the condition. In 2020, Regeneron paused dosing in a mid-stage trial of the drug after five patient deaths, ultimately discontinuing the study and working with global regulators to design the late-stage trial, according to the company. The condition affects roughly 1 in 2 million people worldwide, with around 800 to 900 active diagnosed cases globally, according to data from the National Institutes of Health.

Yahoo Finance
Aug 6th, 2026
FDA requests Phase 3 trial for Mirum's Volixibat, delaying NDA until H1 2027 — MIRM stock crashes 15%

Mirum Pharmaceuticals shares plunged 15% on Thursday after the FDA recommended an additional Phase 3 study for its liver disease candidate Volixibat, potentially delaying the new drug application until the first half of 2027. Citizens lowered its price target to $137 from $146 whilst maintaining an Outperform rating. The regulatory setback overshadowed strong second-quarter results. Mirum reported revenue of $176.2 million, beating analysts' estimates of $167.3 million. The company raised its full-year net product sales guidance to $680 million to $700 million, from $660 million to $680 million. Mirum ended the quarter with $561.3 million in cash and equivalents. Volixibat has already received FDA Breakthrough Therapy and Orphan Drug designations.

Yahoo Finance
Aug 6th, 2026
Mirum raises 2026 guidance to $700M, delays PSC drug filing amid FDA review

Mirum Pharmaceuticals raised its full-year 2026 net product sales guidance to $680 million to $700 million, citing growth in Alagille syndrome and expanding adult PFIC diagnosis. The company secured $690 million through a convertible note offering, improving its capital structure whilst settling 75% of 2029 notes. The firm identified a significant opportunity in adult PFIC, estimating at least 2,000 addressable patients each in the US and Europe. Commercial operations achieved a high-50s percent cash contribution margin, representing a 5 percentage point year-over-year improvement. Mirum delayed its volixibat PSC NDA submission due to alignment issues with FDA reviewers but received Breakthrough Therapy Designation. The company targets a first-half 2027 NDA submission for PSC and anticipates Phase III PBC results in Q1 2027.

Yahoo Finance
Aug 6th, 2026
Mirum Pharmaceuticals' Q2 revenue hits $176M, up 38% year-on-year despite widened loss

Mirum Pharmaceuticals reported revenue of $176.24 million for the quarter ended June 2026, up 37.9% year-over-year. The figure exceeded the consensus estimate of $164.76 million by 6.97%. The company posted a loss of $0.80 per share, compared to $0.12 a year ago, slightly missing the estimated loss of $0.77 per share. Product sales showed strong performance across categories. Livmarli generated $128.72 million, surpassing the $119.6 million analyst estimate. Bile acid medicines brought in $47.52 million, also beating expectations of $45.64 million. Despite beating revenue estimates, Mirum's shares fell 18.7% over the past month, underperforming the S&P 500's 3.5% gain.